Abstracts tagged "axial spondyloarthritis and certolizumab pegol"

Abstract Number: 1508 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol-Treated Patients with Non-Radiographic Axial Spondyloarthritis Demonstrate Improvements in Sleep Quality and Other Patient Reported Outcomes
Lianne Gensler ¹, Jonathan Kay ², Walter P. Maksymowych ³, Nigil Haroon ⁴, Lars Bauer ⁵, Bengt Hoepken ⁵, Natasha de Peyrecave ⁶, Thomas Kumke ⁷ and Atul Deodhar⁸, ¹University San Francisco California, San Francisco, CA, ²UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁴Toronto Western Hospital, Krembil Research Institute, University of Toronto, Toronto, ON, Canada, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Monheim, Germany, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Pain, fatigue, morning stiffness and impaired sleep are some of the main symptoms contributing to reduced quality of life (QoL) in patients (pts) with…
Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 671 • 2015 ACR/ARHP Annual Meeting
Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Maxime Dougados¹, Owen Davies², Tommi Nurminen³, Geoffroy Coteur⁴ and Laure Gossec⁵, ¹Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ²UCB Pharma, Slough, United Kingdom, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Sorbonne Universités, UPMC Univ Paris 06 GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière Rheumatology Department, Paris, France
Background/Purpose: Discordance between patient (pt) and physician (phy) assessment of disease activity (DA) in spondyloarthritis (SpA) is recognized, with phys tending to score DA less…
Abstract Number: 2859 • 2015 ACR/ARHP Annual Meeting
Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis
Atul A. Deodhar¹, Joachim Sieper², Owen Davies³, Tommi Nurminen⁴ and Philip J. Mease⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²University Hospital Charité, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Recent studies suggest that patients' (pts') body weight impacts response to anti-TNF treatment in pts with spondyloarthropathies1 including axial spondyloarthritis (axSpA).2 Here we investigate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].